SHELTON, Conn., May 31, 2016 /PRNewswire/ -- NanoViricides, Inc.
(NYSE MKT: NNVC (the "Company") announced today that it has entered
into an agreement with St. Jude Children's Research Hospital,
Memphis, TN, for further drug
development in its anti-influenza program.
NanoViricides, Inc. has previously held a pre-IND meeting with
the US FDA on its anti-influenza drug development program, and
obtained valuable guidance. Since then, the Company has been
performing necessary CMC (chemistry, manufacture, and control)
studies and production scale-up for the identified development
candidate, namely, FluCide™-I. The Company has also continued
further anti-influenza drug development that is anticipated to
result in additional candidates superior to FluCide-I.
The testing of these candidates for anti-influenza activity will
be performed in the laboratory of Dr. Elena
Govorkova in collaboration with Dr. Robert G. Webster and will include both in
vitro and in vivo studies. They have extensive
experience in influenza virus infections with a large number of
different influenza strains, and in anti-viral agents discovery.
The overall objective of these studies will be to help select
clinical drug development candidates for the treatment of influenza
virus in humans, using both the injectable and oral administration
routes. Injectable administration is preferable for hospitalized
patients that are extremely sick, while oral administration is
preferred for out-patients.
The in vitro studies will evaluate the efficacy and
potency of the Company's nanoviricides anti-viral agents against a
panel of influenza A and B virus infection of different types of
cells, including human bronchial epithelial cells. The in
vivo studies in small animals will evaluate the safety and
efficacy of the Company's nanoviricides to protect against severe
H1N1 influenza infection.
The St. Jude influenza research program began in 1968 under the
leadership of renowned virologist Robert G.
Webster, PhD. The research program has provided
important breakthroughs in several major influenza outbreaks over
the years, leading to the designation of St Jude Influenza Program
as a World Health Organization Collaborating Center for Influenza
and a NIH Center of Excellence for Influenza Research and
Surveillance.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral
diseases of the eye including EKC and herpes keratitis, Shingles,
Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
Logo - http://photos.prnewswire.com/prnh/20150107/167444LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-signs-agreement-with-st-jude-childrens-research-hospital-for-further-influenza-drug-development-300276518.html
SOURCE NanoViricides, Inc.